• Recruiting

NCT04973605: Phase 1/2: BGB-11417 in Monotherapy and With Carfilzomib-dex in RRMM and t(11;14)

NCT04973605: Phase 1/2: A Phase 1b/2 Study of BGB-11417 in Monotherapy and in Various Combinations With Dexamethasone and Carfilzomib in Multiple Myeloma

BGB-11417

NCT04973605: Phase 1/2: A Phase 1b/2 Study of BGB-11417 in Monotherapy and in Various Combinations With Dexamethasone and Carfilzomib in Multiple Myeloma


Study consists of two parts, a part 1 dose escalation and a part 2 cohort expansion in combination with dexamethasone and carfilzomib intravenously across two cohorts with a monotherapy component as well.


Sponsor

BeiGene

 

ClinicalTrials.gov Identifier: NCT04973605

Official Title: A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone and Carfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14)

First Posted : July 22, 2021

Click here to see details on ClinicalTrials.gov

 

BGB-11417

Bcl-2 Inhibitor BGB-11417 (Code C175489)

B-cell Lymphoma-2 Inhibitor BGB-11417

Bcl-2 Inhibitor BGB-11417

BGB 11417

BGB-11417

BGB11417

 

Drug: BGB-11417

Drug: Dexamethasone

Drug: Carfilzomib

 

Locations

United States, Alabama

United States, California

United States, Florida

United States, Georgia

United States, Illinois

United States, Maryland

United States, Massachusetts

United States, Michigan

United States, New York

United States, Ohio

United States, Utah

United States, Washington

United States, Wisconsin

Australia, New South Wales

Australia, Victoria

Australia, Western Australia

AustraliaCanada, British Columbia

Canada, Ontario

Canada, Quebec

New Zealand



Posts Archive